<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-30555" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Trazodone</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Shin</surname>
            <given-names>Justin J.</given-names>
          </name>
          <aff>Kaweah Delta Mental Health Hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Saadabadi</surname>
            <given-names>Abdolreza</given-names>
          </name>
          <aff>Western University/ Kaweah Delta</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Justin Shin declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Abdolreza Saadabadi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>29</day>
          <month>2</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-30555.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Trazodone is a medication used in the management and treatment of major depressive disorder. This drug is in the serotonin-antagonist-and-reuptake-inhibitor class of medications; it can be used as a component of combination therapy with other drugs or psychotherapies or as monotherapy for treating depression. Trazodone is&#x000a0;an&#x000a0;antidepressant&#x000a0;that&#x000a0;inhibits serotonin transporter and serotonin type 2 receptors; it&#x000a0;is a&#x000a0;triazolopyridine&#x000a0;derivative. Trazodone inhibits the reuptake of serotonin and blocks the histamine and &#x003b1;-1-adrenergic receptors.&#x000a0;This activity reviews the indications, actions, and contraindications for trazodone as a valuable agent in managing major depression. This activity will highlight the mechanism of actions, adverse effects, and other key factors (eg, off-label uses, dosing, pharmacodynamics, pharmacokinetics, monitoring, and relevant interactions) pertinent to interprofessional team members in treating patients with depression and related conditions.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify appropriate indications for trazodone therapy in psychiatric and non-psychiatric settings.</p></list-item><list-item><p>Differentiate between trazodone and other antidepressants regarding efficacy, safety profile, and potential drug interactions.</p></list-item><list-item><p>Implement evidence-based strategies for titrating trazodone dosage and managing side effects to optimize treatment outcomes.</p></list-item><list-item><p>Collaborate with mental health specialists, pharmacists, and other interprofessional healthcare team members to optimize trazodone therapy and ensure patient safety.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=30555&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=30555">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-30555.s2" sec-type="Indications">
        <title>Indications</title>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <p>Trazodone is an&#x000a0;FDA-approved&#x000a0;antidepressant for treating major depressive disorders.<xref ref-type="bibr" rid="article-30555.r1">[1]</xref>&#x000a0;The drug can be&#x000a0;used as&#x000a0;a component of combination therapy with other drugs or psychotherapies or as monotherapy&#x000a0;for treating depression.<xref ref-type="bibr" rid="article-30555.r2">[2]</xref></p>
        <p>
<bold>Non-FDA-Approved Uses</bold>
</p>
        <p>Trazodone is used&#x000a0;off-label for patients&#x000a0;with insomnia. Trazodone is not FDA-approved for sleep disorders&#x000a0;due to insufficient&#x000a0;clinical data to justify its use as a sedative agent.<xref ref-type="bibr" rid="article-30555.r3">[3]</xref>&#x000a0;Trazodone is also used off-label for anxiety, Alzheimer disease, substance misuse, bulimia, and fibromyalgia due to its serotonergic receptor antagonism and serotonin reuptake-inhibiting effects.<xref ref-type="bibr" rid="article-30555.r4">[4]</xref>&#x000a0;Trazodone has also been used for post-traumatic stress disorder (PTSD) if the first-line treatment of SSRIs does not&#x000a0;demonstrate efficacy. The dose of 50 to 200 mg of trazodone has been shown to reduce nightmare episodes of nightmares as well as improve sleep habits&#x000a0;in studies involving PTSD patients. According to the American Academy of Sleep Medicine (AASM), trazodone is suggested to treat nightmares associated with PTSD.<xref ref-type="bibr" rid="article-30555.r5">[5]</xref> However, various studies&#x000a0;show patients with panic symptoms have&#x000a0;suffered&#x000a0;exacerbation in some instances, which is why SSRIs,&#x000a0;instead of&#x000a0;trazodone,&#x000a0;are preferred as the first-line treatment for PTSD. Additionally, research has shown trazodone&#x000a0;improves apnea and hypopnea&#x000a0;episodes in patients with obstructive sleep apnea (OSA), and the drug does not worsen hypoxemic episodes.<xref ref-type="bibr" rid="article-30555.r6">[6]</xref>&#x000a0;Trazodone raises the respiratory threshold, lowering the risk of respiratory instability.<xref ref-type="bibr" rid="article-30555.r7">[7]</xref></p>
      </sec>
      <sec id="article-30555.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Trazodone is&#x000a0;an&#x000a0;antidepressant&#x000a0;that&#x000a0;inhibits serotonin transporter and serotonin type 2 receptors; it&#x000a0;is a&#x000a0;triazolopyridine&#x000a0;derivative. Trazodone inhibits the reuptake of serotonin and blocks the histamine and &#x003b1;-1-adrenergic receptors.&#x000a0;The drug also induces significant changes in 5-HT presynaptic receptor&#x000a0;adrenoreceptors. The full spectrum of trazodone&#x02019;s mechanism&#x000a0;of action is not fully understood, explaining&#x000a0;its&#x000a0;off-label&#x000a0;uses. Trazodone is in the category of SARI drugs&#x000a0;(serotonin antagonist and reuptake inhibitors), with other members being&#x000a0;phenylpiperazine,&#x000a0;etoperidone,&#x000a0;lorpiprazole, and&#x000a0;mepiprazole.<xref ref-type="bibr" rid="article-30555.r8">[8]</xref></p>
        <p>Clinical studies&#x000a0;have shown&#x000a0;trazodone&#x000a0;is comparable&#x000a0;in&#x000a0;efficacy to other drug classes, such as tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), and serotonin-norepinephrine receptor inhibitors (SNRIs) in treating major depressive disorders. Also, trazodone has better tolerance than second-generation SSRIs, which are&#x000a0;highly associated with insomnia, anxiety, and sexual dysfunction.<xref ref-type="bibr" rid="article-30555.r9">[9]</xref> The unique&#x000a0;property of&#x000a0;trazodone,&#x000a0;which simultaneously&#x000a0;inhibits&#x000a0;SERT, 5-HT2A, and 5-HT2C receptors, avoids the issue of sexual dysfunction, insomnia, and anxiety that commonly presents with SSRI and SNRI therapy.</p>
        <p>Trazodone reduces neurotransmitters associated with arousal effects, such as serotonin, noradrenaline, dopamine, acetylcholine, and histamine. Low-dose trazodone use exerts a sedative effect on sleep through the antagonism of the 5-HT-2A receptor, H1 receptor, and alpha-1-adrenergic receptors.&#x000a0;Furthermore, a recent study on human astrocytes showed&#x000a0;trazodone&#x000a0;helps decrease inflammatory mediator release and helps normalize trophic and metabolic support during inflammation of neurons, which is associated with major depression.</p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:</bold> Peak plasma concentrations are&#x000a0;approximately&#x000a0;achieved within 1 hour of oral administration.&#x000a0;The bioavailability&#x000a0;of trazodone is approximately 100%.<xref ref-type="bibr" rid="article-30555.r10">[10]</xref></p>
        <p><bold>Distribution:</bold> Trazodone has&#x000a0;89% to 95% plasma protein binding.</p>
        <p><bold>Metabolism:</bold>&#x000a0;Trazodone is extensively metabolized by CYP3A4 to an active metabolite, m-chlorophenyl piperazine(m-CPP). Evidence suggests CYP2D6 plays a minor role in the metabolism of trazodone.<xref ref-type="bibr" rid="article-30555.r11">[11]</xref><xref ref-type="bibr" rid="article-30555.r12">[12]</xref></p>
        <p><bold>Excretion:</bold> Trazodone is primarily excreted&#x000a0;via&#x000a0;urine. The terminal elimination half-life of trazodone is 5&#x000a0;to 9 hours.<xref ref-type="bibr" rid="article-30555.r13">[13]</xref></p>
      </sec>
      <sec id="article-30555.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Trazodone is administered via the oral route.&#x000a0;The medication is available in oral tablets of trazodone hydrochloride&#x000a0;50, 100, 150, and 300 mg in the US. It may be administered after meals to decrease lightheadedness and postural hypotension.</p>
        <p><bold>Major depressive disorder:&#x000a0;</bold>Immediate-release formulation: 50 to 100 mg orally 2 or 3 times daily. Start at 25 to 50 mg 2 or 3 times daily, and increase by 50 mg each day every 3 or 4 days to a maximum dosage of 400 mg daily for outpatients and 600 mg daily for inpatients. Dosing should be tapered to discontinue. A study examined the use of trazodone extended-release formulation following IV trazodone.&#x000a0;They began with&#x000a0;an evening administration of 75 to 150 mg before bedtime as a prolonged-release once-a-day administration. This regimen helps optimize its purpose as an antidepressant, eliciting higher compliance.<xref ref-type="bibr" rid="article-30555.r14">[14]</xref>&#x000a0;The dose may be increased every third day, up to 300 mg daily. The dose may be up to 600 mg per day (maximum recommended dose of trazodone) in hospitalized patients. The results of multi-drug regiment studies showed that using citalopram and fluoxetine with trazodone had no significant impact on any alteration of serum level and no increased risk of headache, sedation, or serotonin syndrome.</p>
        <p><bold>Insomnia:</bold> Studies showed that administering 50 to 100 mg per day of trazodone helped nonorganic insomnia due to depressive disorder, with 100 mg dosage as the most effective to improve sleep. Trazodone may be available as immediate-release&#x000a0;(IR) tablets and, in some countries, prolonged-release tablets, oral drops, and injection solutions.&#x000a0;Abrupt discontinuation of trazodone can lead to&#x000a0;nausea, dysphoria, agitation, and sensory disturbances. Gradual tapering is recommended when discontinuing trazodone.<xref ref-type="bibr" rid="article-30555.r15">[15]</xref></p>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Hepatic impairment:&#x000a0;</bold>Trazodone use has not been studied in patients with liver impairment, and&#x000a0;the recommendation is to use trazodone with caution in this population.</p>
        <p><bold>Renal impairment:&#x000a0;</bold>Trazodone use is not studied in patients with renal impairment, and it is recommended to use trazodone cautiously&#x000a0;in this population.<xref ref-type="bibr" rid="article-30555.r16">[16]</xref></p>
        <p><bold>Pregnancy considerations:&#x000a0;</bold>Clinicians&#x000a0;should register pregnant patients with depression in the National Pregnancy Registry for Antidepressants, which monitors pregnancy outcomes in patients exposed to antidepressants during pregnancy. Published literature on trazodone use in pregnant women has not found any associated risks of miscarriage, significant congenital disabilities, or adverse maternal or fetal outcomes.<xref ref-type="bibr" rid="article-30555.r17">[17]</xref>&#x000a0;The clinical study was conducted on 201 pregnant patients with a major depressive disorder history who became euthymic while using antidepressants at the beginning of pregnancy.&#x000a0;The study showed that patients who discontinued antidepressants during pregnancy have more chances of experiencing a relapse of major depression than women who continued treatment with antidepressants. Therefore, it is advisable to consider the risk of untreated depression if planning to discontinue or change antidepressant treatment while a patient is pregnant or postpartum.</p>
        <p><bold>Breastfeeding considerations:&#x000a0;</bold>Trazodone is excreted in human milk, and no data shows its effect on milk production.<xref ref-type="bibr" rid="article-30555.r18">[18]</xref> Postmarketing reports&#x000a0;provide limited data, and&#x000a0;these reports have not identified an association of adverse effects of trazodone use on the breastfed child. The maternal need for trazodone should be assessed along with the risk of&#x000a0;development and health benefits of breastfeeding the child. According to the safety scoring system use of trazodone should be used cautiously while breastfeeding, especially for infants.<xref ref-type="bibr" rid="article-30555.r19">[19]</xref></p>
        <p><bold>Pediatric patients</bold><bold>:&#x000a0;</bold>FDA has issued&#x000a0;a boxed warning on an increased risk of suicidal thoughts and behaviors in pediatric patients with antidepressant medication use. Additionally, the efficacy and safety of trazodone in the pediatric population have not been established.</p>
        <p><bold>Older patients:&#x000a0;</bold>The dose for older patients should&#x000a0;be reduced&#x000a0;to 100 mg per day.&#x000a0;Trazodone should be used carefully in&#x000a0;older patients as serotonergic antidepressants are associated with hyponatremia in&#x000a0;these patients, who are already at greater risk for this adverse reaction.<xref ref-type="bibr" rid="article-30555.r20">[20]</xref></p>
      </sec>
      <sec id="article-30555.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>The primary adverse effects of trazodone include headaches, fatigue, dizziness, drowsiness,&#x000a0;and somnolence. Other risks include anticholinergic effects (dry mouth), orthostatic hypotension, syncope, QT prolongation, Torsade de pointes, priapism, and&#x000a0;increased suicidal thoughts. QT prolongation and arrhythmia risks&#x000a0;are&#x000a0;due to the interaction of trazodone with&#x000a0;hERG&#x000a0;potassium channels.</p>
        <p>Antidepressants are associated with an increased risk of suicidal thinking, especially in younger adults, adolescents, and children. Despite the presence of anticholinergic effects, the risk of urinary retention and constipation is less than tricyclic antidepressants, such as imipramine or amitriptyline.&#x000a0;The risk for orthostatic hypotension is higher in older patients, especially those&#x000a0;with pre-existing heart conditions, due to the adrenergic &#x003b1;1-receptor blockade.&#x000a0;Patients typically show adverse effects&#x000a0;of somnolence and hypotension during the first week of administration.&#x000a0;Special care is necessary for&#x000a0;male patients with sickle cell anemia, multiple myeloma, leukemia,&#x000a0;autonomic&#x000a0;dysfunction,&#x000a0;hypercoagulable&#x000a0;state, or those with a penile anatomic variation such as angulation,&#x000a0;cavernosal&#x000a0;fibrosis, or&#x000a0;Peyronie disease, as&#x000a0;the drug can cause priapism in these individuals.<xref ref-type="bibr" rid="article-30555.r21">[21]</xref></p>
        <p>In some cases, trazodone use has correlated with visual hallucinations.&#x000a0;Hallucinations generally&#x000a0;resolve with the discontinuation of trazodone, and&#x000a0;clinicians should switch the patient to&#x000a0;another antidepressant medication.<xref ref-type="bibr" rid="article-30555.r22">[22]</xref>&#x000a0;Before initiating trazodone,&#x000a0;obtain a personal and family history of bipolar disorder.&#x000a0;Trazodone-induced&#x000a0;mania has been reported.<xref ref-type="bibr" rid="article-30555.r23">[23]</xref>&#x000a0;Bleeding risk is a potential complication associated with trazodone, although the risk is lower than with other antidepressants.<xref ref-type="bibr" rid="article-30555.r24">[24]</xref></p>
        <p>
<bold>Boxed Warning</bold>
</p>
        <p>Antidepressants, including trazodone, increase the risk of&#x000a0;suicide in young adult and&#x000a0;pediatric patients. Closely monitoring trazodone-treated patients for suicidal ideation and&#x000a0;behaviors&#x000a0;is necessary. Closely monitor all antidepressant-treated patients for clinical worsening and the emergence of suicidal thoughts and behaviors.<xref ref-type="bibr" rid="article-30555.r25">[25]</xref></p>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>CNS depressants: Trazodone&#x000a0;can increase the CNS depression induced by&#x000a0;alcohol and benzodiazepines and increase the risk of falls and injury.<xref ref-type="bibr" rid="article-30555.r26">[26]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>CYP3A4 inhibitors: Consider dose reduction of trazodone due to increased bioavailability. Administration with clarithromycin increased&#x000a0;exposure, elimination half-life, and peak plasma concentration of trazodone.&#x000a0;Trazodone also reduces the clearance of trazodone, increasing the potential for adverse effects.<xref ref-type="bibr" rid="article-30555.r27">[27]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>CYP3A4 inducers: Carbamazepine, an inducer of CYP3A4, reduces plasma concentration of trazodone.<xref ref-type="bibr" rid="article-30555.r28">[28]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-30555.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Trazodone therapy requires careful consideration for patients&#x000a0;treated&#x000a0;with monoamine&#x000a0;oxidase inhibitors&#x000a0;(MAOIs),&#x000a0;including&#x000a0;linezolid or intravenous methylene blue. MAO inhibitors impair serotonin metabolism, and concurrent administration increases serum levels of serotonin. Therefore,&#x000a0;the patient must&#x000a0;be MAOI-free for 14 days before initiating treatment with&#x000a0;trazodone to reduce the risk of serotonin syndrome. In addition, concomitant use of other serotonergic drugs, such as&#x000a0;triptans, TCA, or fentanyl, will also increase serotonin levels. Trazodone use requires caution in patients with compromised liver function and renal function.<xref ref-type="bibr" rid="article-30555.r29">[29]</xref></p>
      </sec>
      <sec id="article-30555.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Baseline liver functions require monitoring before&#x000a0;and periodically during therapy in patients&#x000a0;starting on trazodone. Patients receiving trazodone should also be monitored for suicidal ideation, especially at the beginning of the treatment or following a dose increase.&#x000a0;Clinicians should&#x000a0;also monitor for signs or symptoms of serotonin syndrome.&#x000a0;In addition, concomitant administration of CYP 3A4&#x000a0;inhibitors&#x000a0;can lead to increased serum trazodone levels,&#x000a0;increasing&#x000a0;the risk of serotonin syndrome and cardiovascular adverse effects.<xref ref-type="bibr" rid="article-30555.r30">[30]</xref>&#x000a0;</p>
        <p>Clinicians&#x000a0;should assess the response to trazodone therapy and consider augmenting or switching antidepressants if an inadequate response occurs.&#x000a0;For patients on digoxin therapy, therapeutic drug monitoring is recommended.<xref ref-type="bibr" rid="article-30555.r31">[31]</xref>&#x000a0;Concomitant administration of trazodone with warfarin requires monitoring the patient's PT/INR, possibly because of&#x000a0;protein or substrate binding competition between two agents.<xref ref-type="bibr" rid="article-30555.r32">[32]</xref></p>
      </sec>
      <sec id="article-30555.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Due to trazodone's hepatic and renal metabolism, special care is necessary for patients with severe hepatic and renal impairment. Serotonin syndrome, while rare, is potentially life-threatening, presenting as a triad of mental status alteration, neuromuscular abnormality,&#x000a0;and&#x000a0;autonomic instability.&#x000a0;Initial clinical suspicion&#x000a0;varies&#x000a0;from presenting tremor, clonus, or akathisia. The first steps to address this condition should be discontinuing serotonergic agents, hydration, and controlling&#x000a0;agitation with anxiolytics. The risk is higher with certain antidepressants, antibiotics, migraine medications, antiemetics, and analgesics. Idiopathic drug-induced&#x000a0;liver&#x000a0;injury may result from trazodone administration. The timeframe typically is&#x000a0;3 months, but reported cases require liver transplantation.<xref ref-type="bibr" rid="article-30555.r33">[33]</xref></p>
        <p>Trazodone overdose can precipitate arrhythmias, respiratory arrest, coma, and priapism. A fatal&#x000a0;overdose has been reported after ingesting 6.45 g&#x000a0;of trazodone. Cerebral edema, seizures, and hyponatremia were the presenting clinical features.<xref ref-type="bibr" rid="article-30555.r34">[34]</xref>&#x000a0;Treatment is usually symptomatic and supportive in the case of hypotension and excessive sedation. If priapism occurs, it requires urgent urologist interventuon. Intracavernosal injection (phenylephrine injection) is indicated in patients with ischemic priapism. Monitoring&#x000a0;serum sodium levels and correction is necessary.<xref ref-type="bibr" rid="article-30555.r34">[34]</xref>&#x000a0;The medical team should call the local poison center for up-to-date guidance on trazodone overdose.<xref ref-type="bibr" rid="article-30555.r35">[35]</xref></p>
      </sec>
      <sec id="article-30555.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Clear communication and instruction are necessary to administer medications to patients appropriately. In addition to clinicians being able to communicate with each other, they must feel comfortable being involved in the treatment process. Psychiatrists usually prescribe trazodone for depression and insomnia. The patient usually follows up with their primary care clinician. Pharmacists should check for&#x000a0;drug interactions and alert the prescriber.&#x000a0;Specialty nurses&#x000a0;should educate the patients on the importance of adherence and&#x000a0;the drug's adverse effects.&#x000a0;Clinicians exhibiting appropriate empathy for patients are necessary for patients to disclose their needs to providers.<xref ref-type="bibr" rid="article-30555.r36">[36]</xref>&#x000a0;An interprofessional healthcare team incorporating clinicians, including clinical psychologists and pharmacists, will lead to optimal patient care with minimal adverse events when prescribing trazodone. All team members&#x000a0;must utilize open communication channels with&#x000a0;other clinical staff and be empowered to make therapeutic decisions and suggestions when they note changes in patient conditions.&#x000a0;</p>
      </sec>
      <sec id="article-30555.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=30555&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=30555">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/30555/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=30555">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-30555.s11">
        <title>References</title>
        <ref id="article-30555.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schwasinger-Schmidt</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Macaluso</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Other Antidepressants.</article-title>
            <source>Handb Exp Pharmacol</source>
            <year>2019</year>
            <volume>250</volume>
            <fpage>325</fpage>
            <page-range>325-355</page-range>
            <pub-id pub-id-type="pmid">30194544</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30555.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McQuaid</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Buelt</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Capaldi</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Fuller</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Issa</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Lang</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Hoge</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Oslin</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Sall</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wiechers</surname>
                <given-names>IR</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>The Management of Major Depressive Disorder: Synopsis of the 2022 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline.</article-title>
            <source>Ann Intern Med</source>
            <year>2022</year>
            <month>Oct</month>
            <volume>175</volume>
            <issue>10</issue>
            <fpage>1440</fpage>
            <page-range>1440-1451</page-range>
            <pub-id pub-id-type="pmid">36122380</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30555.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sateia</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Buysse</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Krystal</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Neubauer</surname>
                <given-names>DN</given-names>
              </name>
              <name>
                <surname>Heald</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline.</article-title>
            <source>J Clin Sleep Med</source>
            <year>2017</year>
            <month>Feb</month>
            <day>15</day>
            <volume>13</volume>
            <issue>2</issue>
            <fpage>307</fpage>
            <page-range>307-349</page-range>
            <pub-id pub-id-type="pmid">27998379</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30555.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khouzam</surname>
                <given-names>HR</given-names>
              </name>
            </person-group>
            <article-title>A review of trazodone use in psychiatric and medical conditions.</article-title>
            <source>Postgrad Med</source>
            <year>2017</year>
            <month>Jan</month>
            <volume>129</volume>
            <issue>1</issue>
            <fpage>140</fpage>
            <page-range>140-148</page-range>
            <pub-id pub-id-type="pmid">27744763</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30555.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Morgenthaler</surname>
                <given-names>TI</given-names>
              </name>
              <name>
                <surname>Auerbach</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Casey</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Kristo</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Maganti</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ramar</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Zak</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kartje</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Position Paper for the Treatment of Nightmare Disorder in Adults: An American Academy of Sleep Medicine Position Paper.</article-title>
            <source>J Clin Sleep Med</source>
            <year>2018</year>
            <month>Jun</month>
            <day>15</day>
            <volume>14</volume>
            <issue>6</issue>
            <fpage>1041</fpage>
            <page-range>1041-1055</page-range>
            <pub-id pub-id-type="pmid">29852917</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30555.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smales</surname>
                <given-names>ET</given-names>
              </name>
              <name>
                <surname>Edwards</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Deyoung</surname>
                <given-names>PN</given-names>
              </name>
              <name>
                <surname>McSharry</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Wellman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Velasquez</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Owens</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Orr</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Malhotra</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Trazodone Effects on Obstructive Sleep Apnea and Non-REM Arousal Threshold.</article-title>
            <source>Ann Am Thorac Soc</source>
            <year>2015</year>
            <month>May</month>
            <volume>12</volume>
            <issue>5</issue>
            <fpage>758</fpage>
            <page-range>758-64</page-range>
            <pub-id pub-id-type="pmid">25719754</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30555.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Eckert</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Malhotra</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wellman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>DP</given-names>
              </name>
            </person-group>
            <article-title>Trazodone increases the respiratory arousal threshold in patients with obstructive sleep apnea and a low arousal threshold.</article-title>
            <source>Sleep</source>
            <year>2014</year>
            <month>Apr</month>
            <day>01</day>
            <volume>37</volume>
            <issue>4</issue>
            <fpage>811</fpage>
            <page-range>811-9</page-range>
            <pub-id pub-id-type="pmid">24899767</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30555.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mandrioli</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Protti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mercolini</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>New-Generation, Non-SSRI Antidepressants: Therapeutic Drug Monitoring and Pharmacological Interactions. Part 1: SNRIs, SMSs, SARIs.</article-title>
            <source>Curr Med Chem</source>
            <year>2018</year>
            <volume>25</volume>
            <issue>7</issue>
            <fpage>772</fpage>
            <page-range>772-792</page-range>
            <pub-id pub-id-type="pmid">28707591</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30555.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fagiolini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Comandini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Catena Dell'Osso</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kasper</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Rediscovering trazodone for the treatment of major depressive disorder.</article-title>
            <source>CNS Drugs</source>
            <year>2012</year>
            <month>Dec</month>
            <volume>26</volume>
            <issue>12</issue>
            <fpage>1033</fpage>
            <page-range>1033-49</page-range>
            <pub-id pub-id-type="pmid">23192413</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30555.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hiemke</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bergemann</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Clement</surname>
                <given-names>HW</given-names>
              </name>
              <name>
                <surname>Conca</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Deckert</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Domschke</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Eckermann</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Egberts</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Gerlach</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Greiner</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gr&#x000fc;nder</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Haen</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Havemann-Reinecke</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Hefner</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Helmer</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Janssen</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Jaquenoud</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Laux</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Messer</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>M&#x000f6;ssner</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>M&#x000fc;ller</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Paulzen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pfuhlmann</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Riederer</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Saria</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Schoppek</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Schoretsanitis</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Schwarz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gracia</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Stegmann</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Steimer</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Stingl</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Uhr</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ulrich</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Unterecker</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Waschgler</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Zernig</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Zurek</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Baumann</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017.</article-title>
            <source>Pharmacopsychiatry</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>51</volume>
            <issue>1-02</issue>
            <fpage>9</fpage>
            <page-range>9-62</page-range>
            <pub-id pub-id-type="pmid">28910830</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30555.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Odagaki</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Toyoshima</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Yamauchi</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Trazodone and its active metabolite m-chlorophenylpiperazine as partial agonists at 5-HT1A receptors assessed by [35S]GTPgammaS binding.</article-title>
            <source>J Psychopharmacol</source>
            <year>2005</year>
            <month>May</month>
            <volume>19</volume>
            <issue>3</issue>
            <fpage>235</fpage>
            <page-range>235-41</page-range>
            <pub-id pub-id-type="pmid">15888508</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30555.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wen</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Rodrigues</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Detection of novel reactive metabolites of trazodone: evidence for CYP2D6-mediated bioactivation of m-chlorophenylpiperazine.</article-title>
            <source>Drug Metab Dispos</source>
            <year>2008</year>
            <month>May</month>
            <volume>36</volume>
            <issue>5</issue>
            <fpage>841</fpage>
            <page-range>841-50</page-range>
            <pub-id pub-id-type="pmid">18238857</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30555.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kale</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Agrawal</surname>
                <given-names>YK</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics of single oral dose trazodone: a randomized, two-period, cross-over trial in healthy, adult, human volunteers under fed condition.</article-title>
            <source>Front Pharmacol</source>
            <year>2015</year>
            <volume>6</volume>
            <fpage>224</fpage>
            <pub-id pub-id-type="pmid">26483693</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30555.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fiorentini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rovera</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Caldiroli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Arici</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Prunas</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Di Pace</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Paletta</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pozzoli</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Buoli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Altamura</surname>
                <given-names>AC</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of oral trazodone slow release following intravenous administration in depressed patients: a naturalistic study.</article-title>
            <source>Riv Psichiatr</source>
            <year>2018</year>
            <season>Sep-Oct</season>
            <volume>53</volume>
            <issue>5</issue>
            <fpage>261</fpage>
            <page-range>261-266</page-range>
            <pub-id pub-id-type="pmid">30353201</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30555.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Menza</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Withdrawal syndrome in a depressed patient treated with trazodone.</article-title>
            <source>Am J Psychiatry</source>
            <year>1986</year>
            <month>Sep</month>
            <volume>143</volume>
            <issue>9</issue>
            <fpage>1195</fpage>
            <pub-id pub-id-type="pmid">3752308</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30555.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nagler</surname>
                <given-names>EV</given-names>
              </name>
              <name>
                <surname>Webster</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Vanholder</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Zoccali</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Antidepressants for depression in stage 3-5 chronic kidney disease: a systematic review of pharmacokinetics, efficacy and safety with recommendations by European Renal Best Practice (ERBP).</article-title>
            <source>Nephrol Dial Transplant</source>
            <year>2012</year>
            <month>Oct</month>
            <volume>27</volume>
            <issue>10</issue>
            <fpage>3736</fpage>
            <page-range>3736-45</page-range>
            <pub-id pub-id-type="pmid">22859791</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30555.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Einarson</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bonari</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Voyer-Lavigne</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Addis</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Matsui</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Koren</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>A multicentre prospective controlled study to determine the safety of trazodone and nefazodone use during pregnancy.</article-title>
            <source>Can J Psychiatry</source>
            <year>2003</year>
            <month>Mar</month>
            <volume>48</volume>
            <issue>2</issue>
            <fpage>106</fpage>
            <page-range>106-10</page-range>
            <pub-id pub-id-type="pmid">12655908</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30555.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Saito</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ishii</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mito</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Yakuwa</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kawasaki</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Tachibana</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Suzuki</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Yamatani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sago</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Murashima</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Trazodone Levels in Maternal Serum, Cord Blood, Breast Milk, and Neonatal Serum.</article-title>
            <source>Breastfeed Med</source>
            <year>2021</year>
            <month>Nov</month>
            <volume>16</volume>
            <issue>11</issue>
            <fpage>922</fpage>
            <page-range>922-925</page-range>
            <pub-id pub-id-type="pmid">34348038</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30555.r19">
          <label>19</label>
          <element-citation publication-type="book">
            <chapter-title>Trazodone</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2022</year>
            <month>4</month>
            <day>18</day>
            <pub-id pub-id-type="pmid">30000237</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30555.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Viramontes</surname>
                <given-names>TS</given-names>
              </name>
              <name>
                <surname>Truong</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Linnebur</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>Antidepressant-Induced Hyponatremia in Older Adults.</article-title>
            <source>Consult Pharm</source>
            <year>2016</year>
            <month>Mar</month>
            <volume>31</volume>
            <issue>3</issue>
            <fpage>139</fpage>
            <page-range>139-50</page-range>
            <pub-id pub-id-type="pmid">26975593</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30555.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Haria</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fitton</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>McTavish</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Trazodone. A review of its pharmacology, therapeutic use in depression and therapeutic potential in other disorders.</article-title>
            <source>Drugs Aging</source>
            <year>1994</year>
            <month>Apr</month>
            <volume>4</volume>
            <issue>4</issue>
            <fpage>331</fpage>
            <page-range>331-55</page-range>
            <pub-id pub-id-type="pmid">8019056</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30555.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Santos</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Moreira</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>Distressing Visual Hallucinations after Treatment with Trazodone.</article-title>
            <source>Case Rep Psychiatry</source>
            <year>2017</year>
            <volume>2017</volume>
            <fpage>6136914</fpage>
            <pub-id pub-id-type="pmid">28702268</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30555.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lai</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zheng</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Fan the flame: trazodone-induced mania in a unipolar depressed patient with stable sertraline treatment.</article-title>
            <source>Neuropsychiatr Dis Treat</source>
            <year>2017</year>
            <volume>13</volume>
            <fpage>2251</fpage>
            <page-range>2251-2254</page-range>
            <pub-id pub-id-type="pmid">28883733</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30555.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bixby</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>VandenBerg</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bostwick</surname>
                <given-names>JR</given-names>
              </name>
            </person-group>
            <article-title>Clinical Management of Bleeding Risk With Antidepressants.</article-title>
            <source>Ann Pharmacother</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>53</volume>
            <issue>2</issue>
            <fpage>186</fpage>
            <page-range>186-194</page-range>
            <pub-id pub-id-type="pmid">30081645</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30555.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kurian</surname>
                <given-names>BT</given-names>
              </name>
              <name>
                <surname>Ray</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Arbogast</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Fuchs</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Dudley</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Cooper</surname>
                <given-names>WO</given-names>
              </name>
            </person-group>
            <article-title>Effect of regulatory warnings on antidepressant prescribing for children and adolescents.</article-title>
            <source>Arch Pediatr Adolesc Med</source>
            <year>2007</year>
            <month>Jul</month>
            <volume>161</volume>
            <issue>7</issue>
            <fpage>690</fpage>
            <page-range>690-6</page-range>
            <pub-id pub-id-type="pmid">17606833</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30555.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Amari</surname>
                <given-names>DT</given-names>
              </name>
              <name>
                <surname>Juday</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Frech</surname>
                <given-names>FH</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Atkins</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Wickwire</surname>
                <given-names>EM</given-names>
              </name>
            </person-group>
            <article-title>Falls, healthcare resources and costs in older adults with insomnia treated with zolpidem, trazodone, or benzodiazepines.</article-title>
            <source>BMC Geriatr</source>
            <year>2022</year>
            <month>Jun</month>
            <day>04</day>
            <volume>22</volume>
            <issue>1</issue>
            <fpage>484</fpage>
            <pub-id pub-id-type="pmid">35658904</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30555.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Farkas</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Volak</surname>
                <given-names>LP</given-names>
              </name>
              <name>
                <surname>Harmatz</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>von Moltke</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Court</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Greenblatt</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Short-term clarithromycin administration impairs clearance and enhances pharmacodynamic effects of trazodone but not of zolpidem.</article-title>
            <source>Clin Pharmacol Ther</source>
            <year>2009</year>
            <month>Jun</month>
            <volume>85</volume>
            <issue>6</issue>
            <fpage>644</fpage>
            <page-range>644-50</page-range>
            <pub-id pub-id-type="pmid">19242403</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30555.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Otani</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ishida</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kaneko</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mihara</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ohkubo</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Osanai</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Sugawara</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Effects of carbamazepine coadministration on plasma concentrations of trazodone and its active metabolite, m-chlorophenylpiperazine.</article-title>
            <source>Ther Drug Monit</source>
            <year>1996</year>
            <month>Apr</month>
            <volume>18</volume>
            <issue>2</issue>
            <fpage>164</fpage>
            <page-range>164-7</page-range>
            <pub-id pub-id-type="pmid">8721280</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30555.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Carvalhana</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Oliveira</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ferreira</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Resende</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Perdigoto</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Barroso</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Acute Liver Failure due to Trazodone and Diazepam.</article-title>
            <source>GE Port J Gastroenterol</source>
            <year>2017</year>
            <month>Jan</month>
            <volume>24</volume>
            <issue>1</issue>
            <fpage>40</fpage>
            <page-range>40-42</page-range>
            <pub-id pub-id-type="pmid">28848778</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30555.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jarema</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dudek</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Landowski</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Heitzman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rabe-Jab&#x00142;o&#x00144;ska</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rybakowski</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>[Trazodon--the antidepressant: mechanism of action and its position in the treatment of depression].</article-title>
            <source>Psychiatr Pol</source>
            <year>2011</year>
            <season>Jul-Aug</season>
            <volume>45</volume>
            <issue>4</issue>
            <fpage>611</fpage>
            <page-range>611-25</page-range>
            <pub-id pub-id-type="pmid">22232986</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30555.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rauch</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Jenike</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Digoxin toxicity possibly precipitated by trazodone.</article-title>
            <source>Psychosomatics</source>
            <year>1984</year>
            <month>Apr</month>
            <volume>25</volume>
            <issue>4</issue>
            <fpage>334</fpage>
            <page-range>334-5</page-range>
            <pub-id pub-id-type="pmid">6718667</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30555.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Small</surname>
                <given-names>NL</given-names>
              </name>
              <name>
                <surname>Giamonna</surname>
                <given-names>KA</given-names>
              </name>
            </person-group>
            <article-title>Interaction between warfarin and trazodone.</article-title>
            <source>Ann Pharmacother</source>
            <year>2000</year>
            <month>Jun</month>
            <volume>34</volume>
            <issue>6</issue>
            <fpage>734</fpage>
            <page-range>734-6</page-range>
            <pub-id pub-id-type="pmid">10860134</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30555.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jurek</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Nourredine</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Megarbane</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>d'Amato</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Dorey</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Rolland</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>[The serotonin syndrome: An updated literature review].</article-title>
            <source>Rev Med Interne</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>40</volume>
            <issue>2</issue>
            <fpage>98</fpage>
            <page-range>98-104</page-range>
            <pub-id pub-id-type="pmid">30243558</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30555.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Avila</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>Fatal Cerebral Edema, Seizures, and Hyponatremia After Trazodone Overdose.</article-title>
            <source>Clin Neuropharmacol</source>
            <year>2017</year>
            <season>Sep/Oct</season>
            <volume>40</volume>
            <issue>5</issue>
            <fpage>221</fpage>
            <page-range>221-223</page-range>
            <pub-id pub-id-type="pmid">28816830</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30555.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wen</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Munarriz</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>McAuley</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Goldstein</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Traish</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Management of ischemic priapism with high-dose intracavernosal phenylephrine: from bench to bedside.</article-title>
            <source>J Sex Med</source>
            <year>2006</year>
            <month>Sep</month>
            <volume>3</volume>
            <issue>5</issue>
            <fpage>918</fpage>
            <page-range>918-922</page-range>
            <pub-id pub-id-type="pmid">16942536</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30555.r36">
          <label>36</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Nichol</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Sundjaja</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Nelson</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <chapter-title>Medical History</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>9</month>
            <day>4</day>
            <pub-id pub-id-type="pmid">30484996</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
